cas 2927-71-1|| where to buy 2,4-Dichloro-5-fluoropyrimidine

Nom du produit:2,4-Dichloro-5-fluoropyrimidine

IUPAC Name:2,4-dichloro-5-fluoropyrimidine

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM219871-500g	in stock	ƛǶǶ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2927-71-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2927-71-1; Formule moléculaire:C4HCl2FN2; Point de fusion:-; Code SMILES:FC1=CN=C(Cl)N=C1Cl; Densité:

: Numéro de catalogue:CM219871; Poids moléculaire:166.96; Point d'ébullition:; N° Mdl:MFCD03412264; Stockage:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Abemaciclib; Lilly announced the five-year results of a pre-planned analysis of Phase 3 MonarchE study, which evaluated two years of adjuvant Verzenio® (Abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. Abemaciclib is the first and only CDK4/6 inhibitor approved for the treatment of node-positive, high-risk early breast cancer (EBC) patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.